PITTSFIELD, Mass. — The Accreditation Committee of the College of American Pathologists has awarded accreditation to Nuclea Biotechnologies, based on results of a recent on-site inspection as part of the CAP’s Accreditation Programs.

Nuclea was advised of this national recognition and congratulated for the excellence of the services being provided. Nuclea’s laboratory in Pittsfield is one of more than 7,700 CAP-accredited facilities worldwide.

“We take great pride in the quality and integrity of the products and services that Nuclea offers,” said Patrick Muraca, president and CEO of Nuclea. “CAP certification is the industry standard that we worked diligently to uphold. Our lab was first accredited in 2009 and we’re proud to have been recertified in 2011, 2013, and now 2015.”

The U.S. federal government recognizes the CAP Laboratory Accreditation Program, begun in the early 1960s, as being equal-to or more-stringent-than the government’s own inspection program.

During the CAP accreditation process, designed to ensure the highest standard of care for all laboratory patients, inspectors examine the laboratory’s records and quality control of procedures for the preceding two years. CAP inspectors also examine laboratory staff qualifications, equipment, facilities, safety program and record, and overall management.

Nuclea Biotechnologies develops and commercializes unique diagnostic tests for breast, prostate and other cancers, as well as for diabetes and other chronic diseases leading to novel companion diagnostics for the pharmaceutical and biotechnology industries. Nuclea is at the forefront of proteomics, a more precise, personalized way to monitor chronic disease.

• Most Read

• Most Comments

• All News

• Blogroll

• Photos